Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • AI Infrastructure (Part 2): Powering the AI Buildout

    William Blair macro analyst Richard de Chazal and Jed Dorsheimer, group head of energy and power technologies research, discuss how the political and policy landscape is shaping the power, permitting, and infrastructure needed to support the AI buildout.

    Read more

  • The Leveraged Finance Market Navigates the Changing Seasons

    2026 has been a year of multifaceted uncertainty for borrowers and lenders across the leveraged finance market—but conditions have improved from early-year lows, settling into a trend of solid issuance volume and borrower-friendly pricing.

    Read more

  • AI Infrastructure: What to Expect as Data Centers Head to the Ballot Box

    William Blair’s macro analyst Richard de Chazal and partner and group head of Global Services Tim Mulrooney discuss how growing political scrutiny of data centers could affect the AI infrastructure buildout as the midterm elections approach.

    Listen to the podcast
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures